Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... their 2-year survival expectations. Sequential therapy with either continued ...

Many other clinical trials aimed at optimizing sequential therapy ... Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC) natural history ...

The use of targeted therapies in a neoadjuvant setting, with the aims of significantly reducing tumor volume before surgery and gaining better control of disease in high-risk patients, is a ...